Category: Novartis
Novartis announces promising five-year data for leukaemia treatment Kymriah
Novartis has shared long-term, five-year follow-up results from its pivotal clinical phase 2 trial, ELIANA, evaluating Kymriah (tisagenlecleucel), the first-ever approved CAR T-cell therapy, in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (ALL). Kymriah is a one-off treatment designed to help patients’ immune…
Global DNA Nanotechnology Market Report 2022-2027 Featuring Major Players
DUBLIN, May 20, 2022 /PRNewswire/ — The “Global DNA Nanotechnology Market, By Type, By Application, By End User, By Region, Competition Forecast and Opportunities, 2017-2027” report has been added to ResearchAndMarkets.com‘s offering. Global DNA nanotechnology market is projected to register growth at a significant rate during the forecast period, 2023-2027 with…
